4D Molecular Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
Due Diligence for Asset Managers
Analyze the public filings of asset managers
Dive into the EDGAR, IAPD, CAFR source data
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
4D Molecular Therapeutics Inc
TickerFDMT
CIK #0001650648
CUSIP35104E100
SectorLife Sciences - Biological Products, (No Disgnostic Substances)
Address5858 Horton Street #455, Emeryville, CA 94608
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
4D Molecular Therapeutics Inc 2018-09-11 90.0 M Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001650648] 10-K
[0001650648] 10-Q
[0001650648] 3
[0001650648] 4
[0001650648] 8-K
[0001650648] D
[0001650648] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
State Street Corp 4D Molecular Therapeutics Inc [2026-05-12] 0.0
Janus Henderson Group PLC 4D Molecular Therapeutics Inc [2026-02-17] 0.0
Novo Holdings A/S 4D Molecular Therapeutics Inc [2025-10-20] 0.0
Goldman Sachs Group Inc 4D Molecular Therapeutics Inc [2024-11-06] 6.9
Vanguard Group Inc 4D Molecular Therapeutics Inc [2024-11-04] 5.32
RA Capital Management LP 4D Molecular Therapeutics Inc [2023-06-05] 6.7
Venrock Healthcare Capital Partners III LP 4D Molecular Therapeutics Inc [2023-05-15] 8.7
Janus Henderson Group PLC 4D Molecular Therapeutics Inc [2022-02-11] 5.1
BlackRock Inc 4D Molecular Therapeutics Inc [2022-02-04] 6.5
Deep Track Capital LP 4D Molecular Therapeutics Inc [2021-11-04] 5.69
Biotechnology Value Fund L P 4D Molecular Therapeutics Inc [2021-07-06] 3.9
Kirn David 4D Molecular Therapeutics Inc [2021-02-16] 7.5
Pfizer Inc 4D Molecular Therapeutics Inc [2021-02-16] 6.3
Schaffer David 4D Molecular Therapeutics Inc [2021-02-16] 7.5
FMR LLC 4D Molecular Therapeutics Inc [2021-02-08] 0.0
Ridgeback Capital Investments LP 4D Molecular Therapeutics Inc [2020-12-23] 5.4
Viking Global Investors LP 4D Molecular Therapeutics Inc [2020-12-21] 14.9
Form 3/4/5 Filer 2011 - 2026
4D Molecular Therapeutics Inc
Bizily Scott
Kirn David
Sblendorio Glenn
Theuer Charles
Miller-Rich Nancy
Gray Susannah
Milligan John F
Chacko Jacob
Tomasello Shawn
Simms Christopher Paul
Gupta Ashoo
Humer Kristian
Mehra Uneek
Kamal Fariborz
Kim Robert Young
Shah Rajeev M
RA Capital Healthcare Fund LP
RA Capital Management LP
Kolchinsky Peter
BVF Inc/IL
Biotechnology Value Trading Fund OS LP
BVF Partners L P/IL
Lampert Mark N
BVF GP Holdings LLC
BVF II GP LLC
BVF Partners OS Ltd
Biotechnology Value Fund L P
Biotechnology Value Fund II LP
BVF I GP LLC
Viking Global Opportunities GP LLC
Viking Global Investors LP
Viking Global Opportunities Illiquid Investments Sub-Master
Viking Global Opportunities Parent GP LLC
Viking Global Opportunities Portfolio GP LLC
Halvorsen Ole Andreas
Shabet Rose Sharon
Ott David C
Kasahara Noriyuki
Moretti August J
Fishman Robert S
Zimmermann Carolyne
Schaffer David
Yao Tony DUNG Ling
Burkoth William T
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Simms Christopher Paul
Stock Option (Right to Buy) · derivative
2026-03-25 Grant 219,000 $0.00
Kirn David
Stock Option (Right to Buy) · derivative
2026-03-25 Grant 750,000 $0.00
Bizily Scott
Stock Option (Right to Buy) · derivative
2026-03-25 Grant 217,000 $0.00
Gupta Ashoo
Common Stock
2026-03-20 Sell 80 $8.61 689
Gupta Ashoo
Restricted Stock Units · derivative
2026-03-20 Option exercise 865 $0.00
Gupta Ashoo
Restricted Stock Units · derivative
2026-03-20 Option exercise 221 $0.00
Gupta Ashoo
Common Stock
2026-03-20 Option exercise 221
Gupta Ashoo
Common Stock
2026-03-20 Option exercise 865
Gupta Ashoo
Common Stock
2026-03-20 Sell 310 $8.61 2,669
Sblendorio Glenn
Stock Option (Right to Buy) · derivative
2026-01-05 Grant 45,000 $0.00
Gupta Ashoo
Restricted Stock Units · derivative
2025-12-20 Option exercise 220 $0.00
Gupta Ashoo
Common Stock
2025-12-20 Sell 310 $8.68 2,691
Gupta Ashoo
Common Stock
2025-12-20 Option exercise 220
Gupta Ashoo
Common Stock
2025-12-20 Sell 79 $8.68 686
Gupta Ashoo
Common Stock
2025-12-20 Option exercise 866
Gupta Ashoo
Restricted Stock Units · derivative
2025-12-20 Option exercise 866 $0.00
Bizily Scott
Common Stock
2025-12-16 Option exercise 1,635 $4.14 6,769
Bizily Scott
Stock Option (Right to Buy) · derivative
2025-12-16 Option exercise 1,635 $0.00
Bizily Scott
Common Stock
2025-12-16 Sell 1,635 $10.90 17,822
Theuer Charles
Common Stock
2025-12-12 Option exercise 9,333 $1.14 10,640
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 152 50,836,193
2025-12-31 153 53,505,527
2025-09-30 135 40,129,783
2025-06-30 121 40,550,721
2025-03-31 128 43,080,853
2024-12-31 147 46,738,350
2024-09-30 141 58,725,247
2024-06-30 145 57,905,190
2024-03-31 152 60,939,939
2023-12-31 113 44,708,731
2023-09-30 112 41,932,871
2023-06-30 101 41,410,505
Form 13F Holdings
Firm Period DFND Voting Shares
Assenagon Asset Management SA [2026-06-30] SOLE 83,333 83,333
Ballentine Partners LLC [2026-06-30] OTR 0 16,359
Gamma Investing LLC [2026-06-30] DFND 1,334 1,334
Allied Private Wealth LLC [2026-06-30] SOLE 740 740
Versant Capital Management Inc [2026-06-30] SOLE 728 728
Fortitude Family Office LLC [2026-06-30] SOLE 134 134
Farther Finance Advisors LLC [2026-06-30] SOLE 0 125
IFP Advisors LLC [2026-06-30] SOLE 78 78
True Wealth Design LLC [2026-06-30] SOLE 0 54
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com